The Gynecologic Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1970-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gog.org
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT01489371
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Withdrawn
- Conditions
- Ovarian CarcinomaHereditary Breast and Ovarian Cancer SyndromeFallopian Tube CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- Procedure: Evaluation of Cancer Risk FactorsOther: Medical Chart ReviewOther: Study of Socioeconomic and Demographic Variables
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT01445275
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
Phase 2
Completed
- Conditions
- Stage IB Vulvar Cancer AJCC v7Perioperative/Postoperative ComplicationsStage IVA Vulvar Cancer AJCC v7Stage IA Vulvar Cancer AJCC v7Stage II Vulvar Cancer AJCC v7Stage IIIA Vulvar Cancer AJCC v7Stage IIIB Vulvar Cancer AJCC v7Stage IVB Vulvar Cancer AJCC v6 and v7LymphedemaStage IIIC Vulvar Cancer AJCC v7
- Interventions
- Procedure: Bioelectric Impedance AnalysisProcedure: LymphadenectomyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT01406769
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Conditions
- AnxietyRecurrent Fallopian Tube CarcinomaStage IA Fallopian Tube Cancer AJCC v6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage III Ovarian Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7FatigueNausea and VomitingStage I Ovarian Cancer AJCC v6 and v7
- Interventions
- Procedure: Assessment of Therapy ComplicationsOther: Medical Chart ReviewOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 103
- Registration Number
- NCT01372787
- Locations
- 🇺🇸
Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States
🇺🇸Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States
🇺🇸Hennepin County Medical Center, Minneapolis, Minnesota, United States
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7Stage IA Fallopian Tube Cancer AJCC v6 and v7Stage IC Fallopian Tube Cancer AJCC v6 and v7Stage IB Fallopian Tube Cancer AJCC v6 and v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7
- Interventions
- Procedure: Assessment of Therapy ComplicationsBiological: FilgrastimOther: Pharmacological StudyOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 290
- Registration Number
- NCT01366183
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
Completed
- Conditions
- Endometrial Serous AdenocarcinomaStage II Uterine Corpus CancerStage IV Uterine Corpus CancerStage I Uterine Corpus CancerStage III Uterine Corpus Cancer
- Interventions
- Other: Diagnostic Laboratory Biomarker AnalysisOther: Immunohistochemistry Staining MethodOther: Medical Chart ReviewGenetic: Microarray AnalysisOther: Study of Socioeconomic and Demographic VariablesGenetic: Western Blotting
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 360
- Registration Number
- NCT01344837
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
Phase 1
- Conditions
- Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage IB Cervical Cancer AJCC v6 and v7Stage IIA Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage IIIA Cervical Cancer AJCC v6 and v7Stage IIIB Cervical Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7
- Interventions
- Radiation: External Beam Radiation TherapyRadiation: Internal Radiation Therapy
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT01295502
- Locations
- 🇺🇸
Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Completed
- Conditions
- Primary Peritoneal CarcinomaFallopian Tube CarcinomaOvarian Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 39
- Registration Number
- NCT01295489
- Locations
- 🇺🇸
Billings Clinic Cancer Center, Billings, Montana, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 1
Completed
- Conditions
- Ovarian Mucinous CystadenocarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaRecurrent Fallopian Tube CarcinomaUndifferentiated Ovarian CarcinomaOvarian Brenner TumorOvarian Serous CystadenocarcinomaMalignant Ovarian Mixed Epithelial TumorRecurrent Primary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
- Interventions
- Drug: TLR8 Agonist VTX-2337Other: Diagnostic Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT01294293
- Locations
- 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
Not Applicable
Terminated
- Conditions
- Stage IIC Ovarian CancerStage IIIC Fallopian Tube CancerStage IV Ovarian CancerNausea and VomitingOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaStage IIB Fallopian Tube CancerStage IIIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIIB Ovarian Cancer
- Interventions
- Procedure: Adjuvant TherapyProcedure: Management of Therapy ComplicationsOther: Questionnaire Administration
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 4
- Registration Number
- NCT01275664
- Locations
- 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath